Cardiol Therapeutics Publishes Recurrent Pericarditis Phase II Data
TORONTO, Ontario, July 14, 2026 Cardiol Therapeutics Inc. has announced the publication of its Phase II MAvERIC clinical trial...
anti-inflammatory therapy
Advertisement
CardiolRx Phase II Results Support Heart Disease Therapy
TORONTO, ON, May 7, 2026 Cardiol Therapeutics Inc. announced that results from its Phase II MAvERIC study evaluating CardiolRx™...
CardiolRx Phase II Trial Shows Structural Heart Recovery in Myocarditis
Toronto, December 1, 2025 — New clinical data from the Phase II ARCHER trial reveal that CardiolRx™, Cardiol Therapeutics’...
Orphan Designation for ADPKD Treatment Marks Rare Disease Breakthrough
MONMOUTH, N.J., Sept. 18, 2025 A new investigational therapy, JD-004, has received Orphan Drug Designation (ODD) from the U.S. Food...
Advertisement
